

OIE Reference Laboratory annual reports (RINDERPEST)

Activities in 2020

Name (including Title) of Head of Laboratory (Responsible Official): Toshiyuki TSUTSUI

Name (including Title and Position) of OIE Reference Expert: Takehiro KOKUHO

Email address: takehiro@affrc.go.jp

Address of laboratory: 6-20-1 Josuihoncho, Kodaira, Tokyo, JAPAN

Website: <http://www.naro.affrc.go.jp/english/laboratory/niah/index.html>

Telephone: +81 42 321 1446

Fax: +81 42 325 5122

A: Maintaining Scientific and Technical Skills

1. Did your laboratory perform relevant diagnostic tests for purposes such as disease, diagnosis, screening of animals for export, surveillance, etc. (not for quality control, proficiency testing or staff training)
 - a. For the specified disease?
 - b. For closely related diseases or pathogens?

Disease	Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of tests performed last year	
			Nationally	Internationally
FMD	RT-PCR	Yes (modified)	0	0
CSF	RT-PCR	Yes	19	0
ASF	PCR	Yes	26	0

2. Did your laboratory produce, supply, or import standard reference reagents officially recognised by the OIE for the specified disease or for closely related diseases?

Type of Reagent Available	Related diagnostic test	Produced/Supplied/Imported	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	Name of recipient OIE member countries
PCR kit	RT-PCR	Produce	180,000+ doses	0	
PCR kit	PCR	Produce	180,000+ doses	0	

3. Did your laboratory supply, exchange or receive standard reference reagents and/or other diagnostic reagents for the specified disease

Type of reagent	Related diagnostic test	Supplied by your lab, exchanged or received	Amount	Name of recipient or supplier member country
RPV (vaccines and antisera)	Neutralisation Test	Received	8 vials (vaccine) 7 sets (paired sera)	France UK
Fixed ASFV tissues	IFA	Supplied	2	Taiwan

4. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country for the specified disease or for closely related diseases?

Name of the OIE member country receiving the technical consultancy	Purpose	How the advice was provided
National Institute of Veterinary Research, Vietnam	To improve diagnosis and research capability of CSF and ASF	Visit and educate the staff under MOU. Then, follow up by email and web meetings frequently

5. What method of dissemination of information is most often used by your laboratory? (please provide information on activities for other diseases relevant to maintaining capability for specified disease) [a: Articles published in peer-reviewed journals; b: International conferences; c: National conferences; d: Other]

Rinderpest: c and d. To attend several governmental meetings to discuss and revise national contingency plan and publish some articles in the journals for veterinary officers and professional veterinarians and animal producers.

ASF: a-d. To attend several governmental meetings to discuss and revise national contingency plan and publish some articles in scientific journals or the journals for veterinary officers and professional veterinarians and animal producers. Also attend both International and National conferences to share the information of the disease.

CSF: a-d. To attend several governmental meetings to discuss and revise national contingency plan and publish some articles in scientific journals or the journals for veterinary officers and professional veterinarians and animal producers. Also attend both International and National conferences to share the information of the disease.

6. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

No

7. Did your laboratory implement activities to ensure ongoing capability for the designated disease or closely related disease in the event of loss of the key staff including the OIE Reference Expert?

Activity	Description
Evaluation of diagnosis capability for ISO accreditation	Blind tests for diagnosis capabilities for closely related diseases (Canine distemper virus (CDV; as a substitution of RPV), FMD, CSF) by RT-PCR

B: Laboratory Systems

8. Does your laboratory have a Quality Management System certified according to an International Standard? If YES indicate the name of the quality management system adopted or currently in place. Also attach a scanned certificate of the system.

Yes

JIS Q 17025:2018 (ISO/IEC 17025:2017)

9. Is your laboratory accredited by an international accreditation body? If 'yes' indicate test for which your laboratory is accredited and name of the accreditation body.

Yes
Japan Accreditation Board (JAB)

10. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

No

11. Does your laboratory have a biosecurity system in place to ensure security for the pathogen and materials that may contain the infectious pathogen?

Yes

No

C: Capability to Respond to a Suspected Case

12. In the last year, did your laboratory perform diagnostic tests for the specified pathogen and the disease in order to confirm ongoing capability?

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of tests performed last year
Proficiency test of RT-PCR for CDV (as a substitution of RPV)	Yes (modified)	1

13. Did your laboratory produce vaccines for the specified disease or similar diseases?

Disease	Amount supplied nationally or internationally
RPV (LA-AKO strain)	100,000 doses each for national and international use.

14. Did your laboratory organise or participate in inter-laboratory proficiency tests with any other laboratories for the specified disease or similar diseases?

Role of your laboratory (organiser or participant)	Disease	Test	Number of participating laboratories	Regions of participating OIE member countries
Organiser	CSF	RT-PCR	2	JAPAN

D: Networks and Linkages

15. Did your laboratory organise or participate in scientific meetings for the specified disease?

Title of event	Date	Location	Role (Organiser, speaker, presenter)	Title of work presented
Rinderpest Holding Facility (RHF) web meeting (not scientific)	May, 11/2020	on line	participant	
RHF network six monthly catch up meeting (not scientific)	Feb, 12/2020	on line	participant	
RHF network six monthly catch up meeting (not scientific)	Oct, 20/2020	on line	participant	

16. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes No

17. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease?

Yes No

18. Did your laboratory place expert consultants at the disposal of the OIE?

Yes No

19. Did your laboratory carry out activities to raise awareness and improve capability for this disease in other member countries?

Description of activity	Date	Member countries

E: Biosafety

20. What level of biocontainment is used in your laboratory for (a) storage and (b) handling of potentially infectious material for the specified disease?

Research and diagnosis: BSL3
Vaccine production: BSL2

21. Does your laboratory maintain a structured risk assessment for work with potentially infectious material for the specified disease?

Yes

No

22. Was your laboratory's risk assessment for work with potentially infectious material reviewed in the past year?

Yes

No

23. Does your laboratory have an emergency response plan for biosafety incidents involving potentially infectious material for the specified disease?

Yes

No

F: Research

24. Did your laboratory develop new diagnostic methods for the designated pathogen or disease, or a similar disease?

Disease	Diagnostic Method	Description
CSF	gel-based RT-PCR	To diagnose suspected cases of pigs and wild boar (screening), for domestic use
ASF	gel-based PCR	To diagnose suspected cases of pigs and wild boar (screening), for domestic use

25. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than your own?

Title of study	Duration	Purpose of study	Partners (Institutions)	OIE Member Countries Involved other than your Country
Development of Non-infectious phage Rinderpest PCR controls and proficiency test panels	2018-	To develop a novel RT-PCR assay for RP	USDA/APHIS/FADDL	US

26. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest or a similar pathogen?

Title of Project or Contract	Scope	Name(s) of relevant OIE Reference Laboratories
Strengthening International Responses to Transboundary Animal Diseases	To extend the capacity of global vaccine stockpiles of LA-AKO and RBOK rinderpest vaccine for emergent use	Pirbright Laboratory, CIRAD

27. Additional comments regarding your report (if any):

We are discussing with FAO about a 5-years project to maintain RP vaccine production capability at our laboratory since this year.